AstraZeneca Reports Long-Term Efficacy and Tolerability of Calquence (acalabrutinib) in P-ll ACE-LY-004 Study for MCL

 AstraZeneca Reports Long-Term Efficacy and Tolerability of Calquence (acalabrutinib) in P-ll ACE-LY-004 Study for MCL

AstraZenca Reports Long-Term Efficacy and Tolerability of Calquence (acalabrutinib) in P-ll ACE-LY-004 Study for MCL

Shots:

  • AstraZeneca reported long-term follow-up from the positive P-ll ACE-LY-004 study involves assessing Calquence (acalabrutinib) in adult patients with r/r MCL
  • Result: @median follow up (38.1mos.) 44% of patients either remained on treatment or continued to be followed for survival; median DOR (28.6 mos.); estimated DOR rate @36 mos. (41.9%); m-PFS (22 mos.); estimated PFS rate @6mos. (37.2%); presented at ASH
  • Calquence is a selective BTK inhibitor, binds BTK thereby inhibiting its activity, and is approved for CLL and SLL in the US and for CLL in the EU and several other countries globally

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Royal Haskoning

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post